Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801471 | 1.00 | DDB1 (0.41) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL1802720 | 0.83 | HDAC8 (0.40) | KDM4EMAPTHDAC8 | |
| SCHEMBL1801632 | 0.78 | OPRD1 (0.45) | KDM4EMAPTTHRBGPR119SMN1; SMN2 | |
| SCHEMBL3920513 | 0.78 | OPRD1 (0.45) | KDM4EMAPTTHRBGPR119SMN1; SMN2 | |
| SCHEMBL12656247 | 0.75 | DDB1 (0.38) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL1800888 | 0.72 | OPRD1 (0.44) | KDM4ETHRBGPR119SMN1; SMN2CCR5 | |
| SCHEMBL3919263 | 0.72 | OPRD1 (0.44) | KDM4ETHRBGPR119SMN1; SMN2CCR5 | |
| SCHEMBL13437841 | 0.72 | GPR119 (0.47) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL309804 | 0.71 | RECQL (0.51) | KDM4EGPR119USP2SMN1; SMN2 | |
| SCHEMBL24327634 | 0.71 | RORC (0.45) | DDB1CRBNKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | DDB1 1685/4885CRBN 3470/4885KDM4E 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.